Evidence map›Paper›PMID 34559190›Full record

ArticleBlood advances2021

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function.

Prashant Trikha, Jena E Moseman, Aarohi Thakkar, Amanda R Campbell, Ezgi Elmas, Jennifer A Foltz, Nitin Chakravarti, James R Fitch, Elaine R Mardis, Dean A Lee

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. A comprehensive transcriptome characterization of individual nuclear receptor pathways in the human small intestine.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Prashant TrikhaCellular Therapy and Cancer Immunotherapy Program.
Jena E MosemanCellular Therapy and Cancer Immunotherapy Program.ORCID 0000-0001-6849-3225
Aarohi ThakkarCellular Therapy and Cancer Immunotherapy Program.ORCID 0000-0001-6515-8747
Amanda R CampbellCellular Therapy and Cancer Immunotherapy Program.ORCID 0000-0002-0359-3900
Ezgi ElmasCellular Therapy and Cancer Immunotherapy Program.ORCID 0000-0001-8663-8811
Jennifer A FoltzCellular Therapy and Cancer Immunotherapy Program.ORCID 0000-0001-9158-3464
Nitin ChakravartiCellular Therapy and Cancer Immunotherapy Program.ORCID 0000-0002-6619-953X
James R FitchThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Elaine R MardisThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.ORCID 0000-0002-5892-1553
Dean A LeeCellular Therapy and Cancer Immunotherapy Program.ORCID 0000-0001-6693-5392
Nationwide Children's Hospital · US

Funding

Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-VirotherapyU54CA232561 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CRIPE, TIMOTHY P · 2019 to 2023
$12.1M
NCI NIH HHS U54 CA232561
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that regulates cellular processes in cancer and immunity, including innate immune cell development and effector function. However, the transcriptional repertoire through which AHR mediates these effects remains largely unexplored. To elucidate the transcriptional elements directly regulated by AHR in natural killer (NK) cells, we performed RNA and chromatin immunoprecipitation sequencing on NK cells exposed to AHR agonist or antagonist. We show that mature peripheral blood NK cells lack AHR, but its expression is induced by Stat3 during interleukin-21-driven activation and proliferation, coincident with increased NCAM1 (CD56) expression resulting in a CD56bright phenotype. Compared with control conditions, NK cells expanded in the presence of the AHR antagonist, StemRegenin-1, were unaffected in proliferation or cytotoxicity, had no increase in NCAM1 transcription, and maintained the CD56dim phenotype. However, it showed altered expression of 1004 genes including those strongly associated with signaling pathways. In contrast, NK cells expanded in the presence of the AHR agonist, kynurenine, showed decreased cytotoxicity and altered expression of 97 genes including those strongly associated with oxidative stress and cellular metabolism. By overlaying these differentially expressed genes with AHR chromatin binding, we identified 160 genes directly regulated by AHR, including hallmark AHR targets AHRR and CYP1B1 and known regulators of phenotype, development, metabolism, and function such as NCAM1, KIT, NQO1, and TXN. In summary, we define the AHR transcriptome in NK cells, propose a model of AHR and Stat3 coregulation, and identify potential pathways that may be targeted to overcome AHR-mediated immune suppression.

Indexed as

Receptors, Aryl HydrocarbonTranscriptomeCell DifferentiationKiller Cells, NaturalSignal TransductionReceptors, Aryl Hydrocarbon

Identifiers

PMID34559190
PMCPMC8759121
OpenAlexW3199968596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.